Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305802 | 0.88 | SMN1; SMN2 (0.32) | F2 | |
| SCHEMBL15751638 | 0.83 | EDNRB (0.31) | — | |
| SCHEMBL10193636 | 0.79 | PLA2G10 (0.46) | F2PLGPRSS1PRSS2C1S | |
| SCHEMBL305147 | 0.77 | PLA2G10 (0.45) | F2PLGPRSS1PRSS2C1S | |
| SCHEMBL305149 | 0.77 | PLA2G10 (0.45) | F2PLGPRSS1PRSS2C1S | |
| SCHEMBL10193635 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL304833 | 0.76 | ALDH1A1 (0.46) | — | |
| SCHEMBL304835 | 0.76 | ALDH1A1 (0.46) | — | |
| SCHEMBL4602713 | 0.72 | CA2 (0.50) | — | |
| SCHEMBL4602719 | 0.72 | CA2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | F2 2582/4885PLG 1829/4885PRSS1 252/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | F2 2582/4885PLG 1829/4885PRSS1 252/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | F2 2795/4885PLG 2035/4885PRSS1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.